Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, Pain, Transcranial Direct Current Stimulation, tDCS
Brief summary
Pain is a common symptom experienced by people with MS and can significantly interfere with participation in the activities of daily living and adversely affect health-related quality of life. Pain in people with MS has the potential to become chronic, as a consequence of neuronal reorganization. Transcranial Direct Current Stimulation (tDCS) promotes the modulation of brain activity and its prolonged and continuous application can effect plastic modification. Combining tDCS with rehabilitation treatment may have effect in reducing pain in people with MS. This is a pilot randomized control trial to test the effects of tDCS in MS-related pain rehabilitation, its efficacy on pain (intensity, quality, interference with physical functioning), catastrophizing, emotional functioning and quality of life. Furthermore, we will explore the effects on pressure pain threshold and EEG recording. Correlations between sample characteristics and pain features will be investigated. Considering role of tDCS on neuropsychological functions, selective attention will be assessed.
Interventions
DEVICEReal-tDCS + rehabilitation programme
tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
DEVICESham-tDCS + rehabilitation programme
The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
Sponsors
University Hospital of Ferrara
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* chronic pain defined as a constant or intermittent sensory symptom with unpleasant feelings or pain, lasting more than 3 months with a minimum score of 3 points on the Numeric Rating Scale (NRS) for pain perception; * lack of MS worsening in the three months just before the intervention period; * cognitive functioning to give informed consent identified by a Mini-Mental Status Examination (MMSE) score ≥ 24/30.
Exclusion criteria
* worsening of MS-related conditions or changes in drug therapy or any other confounding factor during the study; * rehabilitation treatments or Botulinum toxin injections during the three months preceding the start of the study; * intracranial metal implants that can be stimulated, incorrectly positioned, or overheated by the electric current; * severe cardiopulmonary, renal, and hepatic diseases; * pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numeric Rating Scale (NRS) | 4 weeks | Core outcome measure of pain intensity in chronic pain treatments' clinical trials |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brief Pain Inventory (BPI) | 1 week, 4 weeks, 8 weeks | Assessment of the extent to which pain interferes with general activity, mood, walking, work, relationship with others, sleep, and enjoyment of life. |
| Pain Catastrophizing Scale (PCS) | 1 week, 4 weeks, 8 weeks | Assessment of a tendency to misinterpret or exaggerate apparently threatening situations that can lead to increased sensitivity to pain. |
| Coping Strategies Questionnaire (CSQ) | 1 week, 4 weeks, 8 weeks | Assessment of the frequency of coping strategies in response to pain. |
| Beck Depression Inventory II (BDI-II) | 1 week, 4 weeks, 8 weeks | Assessment of severity of common depressive symptoms. |
| MS Quality of Life - 54 (MSQOL-54) | 1 week, 4 weeks, 8 weeks | Multidimensional health-related quality of life measure that combines both generic and MS-specific items |
| Short Form McGill Pain Questionnaire (SF-MPQ) | 1 week, 4 weeks, 8 weeks | Assessment of sensory and affective dimensions of typical whole-body pain intensity. |
| Go/No-go Task | 1 week, 4 weeks, 8 weeks | Assessment of selective attention |
| Patient Global Impression of Change (PGIC) | 1 week, 4 weeks, 8 weeks | Measure of participants' assessment of the clinical importance of their improvement or worsening over the course of a treatment |
| Pressure Pain Threshold (PPT) | 1 week, 4 weeks, 8 weeks | PPT is measured to test presence of widespread pressure hyperalgesia as sign of abnormal pain processing. |
| Electroencephalography (EEG) recordings | 1 week, 4 weeks, 8 weeks | EEG data will be recorded to test presence of particular brain activity in condition of pain chronicity and catastrophization. |
| Fatigue Severity Scale (FSS) | 1 week, 4 weeks, 8 weeks | Assessment of common features of fatigue in patients with multiple sclerosis |
Countries
Italy
Contacts
Primary ContactSofia Straudi, MD, PhD
Outcome results
None listed